Proxy Results Form 8 K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As reported below under Item 5.07 of this report, Oncocyte Corporation (the "Company") held a special meeting of stockholders on October 11, 2024 (the "Special Meeting"), at which the Company's stockholders approved an amendment and restatement of the Company's 2018 Equity Incentive Plan (as previously amended, the "Incentive Plan") to: (a) provide for an additional 1,250,000 shares of the Company's common stock to be available for the issuance of equity awards thereunder, such that the total number of shares of common stock that have been made available for issuance since the inception of the Incentive Plan is 2,300,000 shares of common stock, (b) provide that the Board of Directors of the Company (the "Board"), or applicable committee of the Board, may delegate, in its discretion, to one or more of the Company's executive officers, the limited authority to grant awards under the Incentive Plan, subject to the limitations under the Incentive Plan with respect to the participants eligible to receive such awards and any other limitations and guidelines established by the Board, or applicable committee of the Board, with respect to the exercise of such delegated authority, (c) eliminate "fungible share counting" in order to provide that any shares of the Company's common stock granted in connection with any awards will be counted against the number of shares available for the grant of awards under the Incentive Plan as one share for every award, (d) eliminate the limitations on "share recycling" in order to provide that any shares of the Company's common stock tendered in payment of an option, delivered or withheld by the Company to satisfy any tax withholding obligation, covered by a stock-settled award that were not issued upon the settlement of the award, or repurchased by the Company using the proceeds from option exercises, will again be made available for issuance under the Incentive Plan, and (e) eliminate the restrictions in the Incentive Plan that prohibit the terms of any award to provide for vesting, in whole or in part, prior to the date that is one year from the date on which the award is granted, in each case, as contemplated by an Amended and Restated 2018 Equity Incentive Plan (the "Amended and Restated Incentive Plan").

For more information about the Amended and Restated Incentive Plan, see the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting, which was originally filed with the Securities and Exchange Commission on September 25, 2024 (the "Proxy Statement"), the relevant portions of which are incorporated herein by reference. The foregoing description of the Amended and Restated Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended and Restated Incentive Plan, a copy of which is filed as Exhibit 10.1 to this report and is incorporated by reference herein.